Amalgamated Bank Cuts Stock Position in Inhibrx, Inc. (NASDAQ:INBX)

Amalgamated Bank lessened its holdings in Inhibrx, Inc. (NASDAQ:INBX) by 7.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,250 shares of the company’s stock after selling 350 shares during the period. Amalgamated Bank’s holdings in Inhibrx were worth $162,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in INBX. Fox Run Management L.L.C. purchased a new position in shares of Inhibrx in the 3rd quarter valued at $232,000. Swiss National Bank raised its stake in shares of Inhibrx by 2.1% in the 3rd quarter. Swiss National Bank now owns 57,600 shares of the company’s stock valued at $1,057,000 after acquiring an additional 1,200 shares during the period. Citigroup Inc. raised its stake in shares of Inhibrx by 3.4% in the 3rd quarter. Citigroup Inc. now owns 49,244 shares of the company’s stock valued at $904,000 after acquiring an additional 1,611 shares during the period. Eventide Asset Management LLC purchased a new stake in Inhibrx during the 3rd quarter worth $7,964,000. Finally, RA Capital Management L.P. increased its stake in Inhibrx by 22.6% during the 3rd quarter. RA Capital Management L.P. now owns 4,724,207 shares of the company’s stock worth $86,689,000 after buying an additional 870,340 shares during the period. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Inhibrx Stock Performance

Inhibrx stock opened at $34.19 on Friday. Inhibrx, Inc. has a 12-month low of $14.31 and a 12-month high of $39.79. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -6.80 and a beta of 2.87. The company has a debt-to-equity ratio of 17.68, a current ratio of 3.82 and a quick ratio of 3.82. The firm’s fifty day moving average price is $34.58 and its 200 day moving average price is $32.61.

Inhibrx (NASDAQ:INBX) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.66). Inhibrx had a negative return on equity of 678.51% and a negative net margin of 13,408.95%. The firm had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, research analysts forecast that Inhibrx, Inc. will post -5.88 EPS for the current fiscal year.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.